Evidence map›Paper›PMID 29932401›Full record

ArticleTurkish journal of urology2018

Can multiphase CT scan distinguish between papillary renal cell carcinoma type 1 and type 2?

Ahmet Bindayi, Michelle L Mcdonald, Alp T Beksac, Gerant Rivera-Sanfeliz, Ahmed Shabaik, Fiona Hughes, Lejla Aganovic, Donna E Hansel, Ithaar H Derweesh

Open access · greenAbstract read
In one paragraph

Article in Turkish journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ahmet BindayiDepartment of Urology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0002-7992-9423
Michelle L McdonaldDepartment of Urology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0002-2489-3152
Alp T BeksacDepartment of Urology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0001-6742-0040
Gerant Rivera-SanfelizDepartment of Urology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0001-8755-3377
Ahmed ShabaikDepartment of Pathology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0003-1987-3453
Fiona HughesDepartment of Radiology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0001-7799-6553
Lejla AganovicDepartment of Radiology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0002-0909-2832
Donna E HanselDepartment of Pathology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0001-7860-4881
Ithaar H DerweeshDepartment of Urology, UC San Diego Health System, La Jolla, California, USA.ORCID http://orcid.org/0000-0002-8673-0711
UC San Diego Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the utility of multiphase computed tomography (CT) and percutaneous renal mass biopsy (PRMB) in differentiating between papillary renal cell carcinoma (pRCC)-Type 1 and -Type 2, as emerging data have suggested differential enhancement patterns in different renal tumor histologies. MATERIAL AND

methodsRetrospective analysis of 51 patients (23 pRCC-Type 1/28 pRCC-Type 2) who underwent multiphase CT followed by surgery from July 2011 to April 2016 was performed. Data were analyzed between subgroups based on histology. Multiphase CT was analyzed for tumor size, and attenuation [Hounsfield Units (HU)]. Change in HU (ΔHU) was calculated between noncontrast (NC), corticomedullary (CM), nephrographic (N), and delayed (D) phases. Subset analysis was carried out on patients who underwent PRMB prior to surgery.

resultsThere was no difference in median tumor size (pRCC-Type 1 2.8 vs. pRCC-Type 2 2.6 cm, p=0.832). In addition to tumor size being similar between groups, distribution of tumor stages between groups was also similar (p=0.651). Greater proportion of high-grade tumors (III/IV) was noted in pRCC-Type 2 (42.9% vs. 8.7%) (p=0.011). There was no difference in HU values for NC (p=0.961), CM (p=0.118), N (p=0.277), and D (p=0.256) phases, and in ΔHU between CM-NC (p=0.278), N-NC (p=0.316), and D-NC (p=0.103). Thirteen patients underwent percutaneous biopsy, 11 of whom had diagnostic samples. Examination of 10/11 (90.9%) samples accurately predicted correct histology, and of 6/11 (54.5%) samples correctly identified high-vs. low-grade histology.

conclusionOur findings suggest substantial overlap of CT findings, despite pRCC-Type 2 having greater proportion of high-grade tumors. Utility of CT is limited in the differentiation between pRCC subtypes. Patients with suggested pRCC on CT imaging being considered for a non-extirpative strategy should undergo PRMB for risk stratification.

Identifiers

PMID29932401
PMCPMC6016655
OpenAlexW2810248280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.